New drug trial offers hope for painful skin condition

NCT ID NCT07151937

Summary

This study is testing a new drug called LAD191 for adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. Researchers will compare different doses of LAD191 against a placebo and an existing drug (adalimumab) to see which is better at reducing the number of painful lumps and tunnels under the skin. The main goal is to see if LAD191 can help at least half of the participants achieve a 50% reduction in their skin lesions over 16 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.